paromomycin

PreclinicalSmall molecule

DDrugs for Neglected Diseases

paromomycin is one of 61 small molecule programs targeting Pulmonary Tuberculosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary TuberculosisActive, not recruiting

AdultRecruiting

Pulmonary TuberculosisPreclinical

Active, not recruiting

AdultPreclinical

Recruiting

Competition

Competitive Landscape

120 competitors in Adult

#DrugCompanyPhaseTrials

Nydrazid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

1 2

Tebrazid

AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Phase 3

1 3

Mounjaro

Eli Lilly

Phase 2

1 4

Rifampicin

Boehringer Ingelheim

Phase 3

3 5

Opzelura

DDizal Pharmaceuticals

Phase 2

1 6

Skyclarys

Biogen

Phase 1

3 7

Sunlenca

Gilead

Phase 1

1 8

NM8074

NNovelMed Therapeutics

Phase 2

2 9

Emtriva

Gilead

Preclinical

1 10

Lupron

Sun Pharmaceutical Industries, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Adult

NCT06907498

Clinical

Trials by Indication[1]

Cutaneous Leishmaniasis3 trials

Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis

Completed·FFundacion Nacional de Dermatologia·Phase 2/3·NCT03829917·120 enrolled

Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis

No longer available·UU.S. Army Medical Research and Development Command··NCT01641796

Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama

Completed·UU.S. Army Medical Research and Development Command·Phase 3·NCT01790659·399 enrolled

Visceral Leishmaniasis3 trials

LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study

Completed·DDrugs for Neglected Diseases·Phase 2·NCT05957978·52 enrolled

Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

Completed·DDrugs for Neglected Diseases·Phase 3·NCT03129646·439 enrolled

An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis

Completed·—·Phase 3·NCT00629031·329 enrolled

Pulmonary Tuberculosis1 trial

Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis

Completed·FFDA Office of Orphan Products Development·N/A·NCT00004444·24 enrolled

Treatment1 trial

Short Course Regimens for Treatment of PKDL (Sudan)

Unknown status·DDrugs for Neglected Diseases·Phase 2·NCT03399955·110 enrolled

Adult1 trial

Paromomycin or Metronidazole for Symptomatic Dientamoeba Fragilis in Adults

Recruiting·SSheba Medical Center·N/A·NCT06907498·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for paromomycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — paromomycin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for paromomycin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Drugs for Neglected Diseases company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: DDrugs for Neglected Diseases

paromomycin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Cutaneous Leishmaniasis3 trials

Visceral Leishmaniasis3 trials

Pulmonary Tuberculosis1 trial

Treatment1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News